Oncolytics Biotech (TSE:ONC) Price Target Raised to C$3.50

Oncolytics Biotech (TSE:ONC) had its price target lifted by Raymond James from C$3.00 to C$3.50 in a research note published on Friday, BayStreet.CA reports.

Oncolytics Biotech Trading Down 2.3 %

Shares of Oncolytics Biotech stock opened at C$1.26 on Friday. The firm has a market capitalization of C$96.84 million, a price-to-earnings ratio of -3.32 and a beta of 1.38. Oncolytics Biotech has a fifty-two week low of C$1.20 and a fifty-two week high of C$3.10. The company has a debt-to-equity ratio of 6.09, a quick ratio of 8.86 and a current ratio of 4.99. The stock has a 50 day moving average of C$1.35 and a 200 day moving average of C$1.42.

Oncolytics Biotech (TSE:ONC) last issued its quarterly earnings data on Thursday, August 1st. The company reported C($0.10) earnings per share for the quarter, hitting the consensus estimate of C($0.10). As a group, research analysts predict that Oncolytics Biotech will post -0.41 earnings per share for the current year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.